Da Penicilina ao Trilhão
Estratégias, Influência e Desvios no Setor Farmacêutico
Palavras-chave:
Setor Farmacêutico , Fraudes, Lobby , Marketing , Saúde individual e coletivaResumo
Manipulações, fraudes, crimes, bilhões destinados a lobby e financiamento eleitoral, interferência indevida em órgãos reguladores e investimentos maciços em marketing estão entre as estratégias recorrentes do setor farmacêutico para maximizar lucros, frequentemente em detrimento da saúde individual e coletiva.
Downloads
Referências
ANGELL, Marcia. The Truth about the Drug Companies: how they deceive us and what to do about it. illustrated edition (2005). New York City, NY, United States: Random House Trade, 2005. 319 p.
APPLEQUIST, Janelle; BALL, Jennifer. An Updated Analysis of Direct-to-Consumer Television Advertisements for Prescription Drugs. The Annals of Family Medicine, [S.L.], v. 16, n. 3, p. 211-216, may. 2018. http://dx.doi.org/10.1370/afm.2220.
AUSTAD, Kirsten E. et al. Medical Students' Exposure to and Attitudes about the Pharmaceutical Industry: a systematic review. Plos Medicine, [S.L.], v. 8, n. 5, p. 1001037, 24 may. 2011. http://dx.doi.org/10.1371/journal.pmed.1001037.
BEKELMAN, Justin E. et al. Scope and Impact of Financial Conflicts of Interest in Biomedical Research. Jama, [S.L.], v. 289, n. 4, p. 454, 22 jan. 2003. http://dx.doi.org/10.1001/jama.289.4.454.
BERENSON, Alex. Merck Agrees to Settle Vioxx Suits for $4.85 Billion. The New York Times. 2007. Available: https://www.nytimes.com/2007/11/09/business/09merck.html. Accessed on: 11 out. 2024.
BINDSLEV, Julie Bolette Brix et al. Underreporting of conflicts of interest in clinical practice guidelines: cross sectional study. Bmc Medical Ethics, [S.L.], v. 14, n. 1, p. 1, 3 may. 2013. http://dx.doi.org/10.1186/1472-6939-14-19.
BRENNAN, Troyen A. et al. Health Industry Practices That Create Conflicts of Interest. Jama, [S.L.], v. 295, n. 4, p. 429, 25 jan. 2006. http://dx.doi.org/10.1001/jama.295.4.429.
CAMARGO JR., Kenneth Rochel de. O grande investimento da indústria farmacêutica nos últimos anos foi para disfunção erétil, não para malária. [Entrevista concedida a Raquel Júnia]. EPSJV/Fiocruz (Escola Politécnica de Saúde Joaquim Venâncio), [Online], nov. 2016. Available: https://www.epsjv.fiocruz.br/noticias/entrevista/o-grande-investimento-da-industria-farmaceutica-nos-ultimos-anos-foi-para Accessed on: 11 oct. 2024.
CHOUDHRY, Niteesh K. et al. Relationships Between Authors of Clinical Practice Guidelines and the Pharmaceutical Industry. Jama, [S.L.], v. 287, n. 5, p. 612, 6 feb. 2002. American Medical Association (AMA). http://dx.doi.org/10.1001/jama.287.5.612.
CITELINE. Pharma Intelligence. Pharma R&D: annual review 2022. London (England): Pharma Intelligence, 2022. 55 p. Available: https://pharmaintelligence.informa.com/. Accessed on: 11 oct. 2024.
COHEN, Deborah et al. Cancer drugs: high price, uncertain value. Bmj, [S.L.], p. 4543, 4 oct. 2017. http://dx.doi.org/10.1136/bmj.j4543.
DANA, Jason; LOEWENSTEIN, George. A Social Science Perspective on Gifts to Physicians from Industry. Jama, [S.L.], v. 290, n. 2, p. 252, 9 jul. 2003. http://dx.doi.org/10.1001/jama.290.2.252.
DEJONG, Colette et al. Pharmaceutical Industry–Sponsored Meals and Physician Prescribing Patterns for Medicare Beneficiaries. Jama Internal Medicine, [S.L.], v. 176, n. 8, p. 1114, 1 aug. 2016. http://dx.doi.org/10.1001/jamainternmed.2016.2765.
DJULBEGOVIC, Benjamin et al. The uncertainty principle and industry sponsored research. The Lancet, [S.L.], v. 356, n. 9230, p. 635 638, aug. 2000. http://dx.doi.org/10.1016/S0140-6736(00)02605-2.
FACHER, Lev. Pharma funded more than 2,400 state lawmaker campaigns in 2020, new STAT analysis finds. STAT. Boston, MA, U.S. jun. 2021. Available: https://www.statnews.com/feature/prescription-politics/state-full-data-set/. Accessed on: 11 oct. 2024.
FLACCO, Maria Elena et al. Head-to-head randomized trials are mostly industry sponsored and almost always favor the industry sponsor. Journal Of Clinical Epidemiology, [S.L.], v. 68, n. 7, p. 811-820, jul. 2015. http://dx.doi.org/10.1016/j.jclinepi.2014.12.016
FOJO, Tito et al. Unintended Consequences of Expensive Cancer Therapeutics - The Pursuit of Marginal Indications and a Me-Too Mentality That Stifles Innovation and Creativity. Jama Otolaryngology-Head & Neck Surgery, [S.L.], v. 140, n. 12, p. 1225, 1 dec. 2014. http://dx.doi.org/10.1001/jamaoto.2014.1570.
FRESQUES, Hannah. Doctors Prescribe More of a Drug If They Receive Money from a Pharma Company Tied to It. ProPublica: Dollars for Doctors. 2019. Available: https://www.propublica.org/article/doctors-prescribe-more-of-a-drug-if-they-receive-money-from-a-pharma-company-tied-to-it. Accessed on: 11 oct. 2024.
GLOY, Viktoria et al. The evidence base of US Food and Drug Administration approvals of novel cancer therapies from 2000 to 2020. International Journal of Cancer, [S.L.], v. 152, n. 12, p. 2474-2484, 24 feb. 2023. http://dx.doi.org/10.1002/ijc.34473.
HARRIS, Gardiner; BERENSON, Alex. 10 Voters on Panel Backing Pain Pills Had Industry Ties. The New York Times. 2005. Available: https://www.nytimes.com/2005/02/25/politics/10-voters-on-panel-backing-pain-pills-had-industry-ties.html. Accessed on: 11 oct. 2024.
HAYES, Michael J.; PRASAD, Vinay. Financial Conflicts of Interest at FDA Drug Advisory Committee Meetings. Hastings Center Report, [S.L.], v. 48, n. 2, p. 10 13, mar. 2018. Wiley. http://dx.doi.org/10.1002/hast.833.
HIGHAM, Scott; BERNSTEIN, Lenny. The Drug Industry’s Triumph over the DEA. The Washington Post. Washington, D.C., U.S. oct. 2017. Available: https://www.washingtonpost.com/graphics/2017/investigations/dea-drug-industry-congress/. Accessed on: 11 oct. 2024.
HOTEZ, Peter J et al. Rescuing the bottom billion through control of neglected tropical diseases. The Lancet, [S.L.], v. 373, n. 9674, p. 1570-1575, may. 2009. http://dx.doi.org/10.1016/s0140-6736(09)60233-6.
KATZ, Dana et al. All Gifts Large and Small. The American Journal of Bioethics, [S.L.], v. 3, n. 3, p. 39-46, aug. 2003. http://dx.doi.org/10.1162/15265160360706552.
KNIGHT, Victoria et al. Pharma Campaign Cash Delivered to Key Lawmakers with Surgical Precision. KFF Health News. oct. 2021. Available: https://kffhealthnews.org/news/article/pharma-campaign-cash-delivered-to-key-lawmakers-with-surgical-precision/. Accessed on: 11 oct. 2024.
KOPP, Emily et al.KFF Health News. 2018. Patient Advocacy Groups Take in Millions From Drugmakers. Is There a Payback? Available: https://kffhealthnews.org/news/patient-advocacy-groups-take-in-millions-from-drugmakers-is-there-a-payback/. Accessed on: 11 oct. 2024.
LEE, Mina et al. Factors Influencing Consumers' Attitudinal and Behavioral Responses to Direct-To-Consumer and Over-the-Counter Drug Advertising. Journal of Health Communication, [S.L.], v. 20, n. 4, p. 431-444, 2 mar. 2015. http://dx.doi.org/10.1080/10810730.2014.965367.
LEXCHIN, J. et al. Pharmaceutical industry sponsorship and research outcome and quality: systematic review. Bmj, [S.L.], v. 326, n. 7400, p. 1167, may. 2003. http://dx.doi.org/10.1136/bmj.326.7400.1167.
LEXCHIN, Joel et al. National patient groups in Canada and their disclosure of relationships with pharmaceutical companies: a cross-sectional study. Bmj Open, [S.L.], v. 12, n. 3, p. 055287, mar. 2022. http://dx.doi.org/10.1136/bmjopen-2021-055287.
LEXCHIN, Joel. Those Who Have the Gold Make the Evidence: how the pharmaceutical industry biases the outcomes of clinical trials of medications. Science And Engineering Ethics, [S.L.], v. 18, n. 2, p. 247-261, 15 feb. 2011. http://dx.doi.org/10.1007/s11948-011-9265-3.
LIGHT, Donald. W.; LEXCHIN, Joel. R. Pharmaceutical research and development: what do we get for all that money?. Bmj, [S.L.], v. 345, n. 071, p. 1-5, 7 aug. 2012. http://dx.doi.org/10.1136/bmj.e4348.
LUNDH, Andreas et al. Industry sponsorship and research outcome: systematic review with meta-analysis. Intensive Care Medicine, [S.L.], v. 44, n. 10, p. 1603-1612, 21 aug. 2018. http://dx.doi.org/10.1007/s00134-018-5293-7.
LURIE, Peter et al. Financial Conflict of Interest Disclosure and Voting Patterns at Food and Drug Administration Drug Advisory Committee Meetings. Jama, [S.L.], v. 295, n. 16, p. 1921, 26 apr. 2006. http://dx.doi.org/10.1001/jama.295.16.1921.
MCCOY, Matthew S. et al. Conflicts of Interest for Patient-Advocacy Organizations. New England Journal of Medicine, [S.L.], v. 376, n. 9, p. 880, mar. 2017. http://dx.doi.org/10.1056/nejmsr1610625.
MCHENRY, Leemon. of Sophists and Spin-Doctors: industry-sponsored ghostwriting and the crisis of academic medicine. Mens Sana Monographs, [S.L.], v. 8, n. 1, p. 129, 2010. http://dx.doi.org/10.4103/0973-1229.58824.
MITCHELL, Aaron P. et al. Financial Relationships with Industry Among National Comprehensive Cancer Network Guideline Authors. Jama Oncology, [S.L.], v. 2, n. 12, p. 1628, 1 dec. 2016. http://dx.doi.org/10.1001/jamaoncol.2016.2710.
MOFFATT, Barton; ELLIOTT, Carl. Ghost Marketing: pharmaceutical companies and ghostwritten journal articles. Perspectives in Biology and Medicine, [S.L.], v. 50, n. 1, p. 18-31, dec. 2007. http://dx.doi.org/10.1353/pbm.2007.0009.
MORGAN, Steven et al. “Breakthrough” drugs and growth in expenditure on prescription drugs in Canada. Bmj, [S.L.], v. 331, n. 7520, p. 815, sep. 2005. http://dx.doi.org/10.1136/bmj.38582.703866.ae.
MOTOLA, Domenico et al. An update on the first decade of the European centralized procedure: how many innovative drugs?. British Journal of Clinical Pharmacology, [S.L.], v. 62, n. 5, p. 610-616, 23 jun. 2006. http://dx.doi.org/10.1111/j.1365-2125.2006.02700.x.
MOYNIHAN, R. Who pays for the pizza? Redefining the relationships between doctors and drug companies. 1. Bmj, [S.L.], v. 326, n. 7400, p. 1189, 2003. http://dx.doi.org/10.1136/bmj.326.7400.1189.
MUKHERJEE, Debabrata et al. Risk of Cardiovascular Events Associated with Selective COX 2 Inhibitors. Jama, [S.L.], v. 286, n. 8, p. 954, 22 aug. 2001. http://dx.doi.org/10.1001/jama.286.8.954.
MULINARI, Shai et al. Five years of pharmaceutical industry funding of patient organisations in Sweden: cross-sectional study of companies, patient organisations and drugs. Plos One, [S.L.], v. 15, n. 6, p. 0235021, 24 jun. 2020. http://dx.doi.org/10.1371/journal.pone.0235021.
NACI, Huseyin et al. Why the drug development pipeline is not delivering better medicines. Bmj, [S.L.], p. 5542, 23 oct. 2015. http://dx.doi.org/10.1136/bmj.h5542.
NEJSTGAARD, Camilla H et al. Association between conflicts of interest and favourable recommendations in clinical guidelines, advisory committee reports, opinion pieces, and narrative reviews: systematic review. Bmj, [S.L.], p. 1-12, 9 dec. 2020. http://dx.doi.org/10.1136/bmj.m4234.
NEUMAN, J. et al. Prevalence of financial conflicts of interest among panel members producing clinical practice guidelines in Canada and United States: cross sectional study. Bmj, [S.L.], v. 343, n. 112, p. 5621, 11 oct. 2011. http://dx.doi.org/10.1136/bmj.d5621.
NYT - The New York Times. Experts and the Drug Industry. Opinion: Editorial. 2005. Available: https://www.nytimes.com/2005/03/04/opinion/experts-and-the-drug-industry.html. Acesso em: 11 out. 2024.
OPEN PAYMENTS - The Open Payments Search Tool. National Transparency Program. Centers for Medicare & Medicaid Services (CMS). Baltimore, MD; U.S. 2024. Available: https://openpaymentsdata.cms.gov/. Accessed on: 11 oct. 2024.
OPENSECRETS - The nation's premier research group tracking money in U.S. politics. 2024. Washington, D.C., U.S. Available: https://www.opensecrets.org/. Accessed on: 11 oct. 2024.
ORLOWSKI, James P.; WATESKA, Leon. The Effects of Pharmaceutical Firm Enticements on Physician Prescribing Patterns. Chest, [S.L.], v. 102, n. 1, p. 270-273, jul. 1992. http://dx.doi.org/10.1378/chest.102.1.270.
ORNSTEIN, Charles et al. We found over 700 doctors who were paid more than a million dollars by drug and medical device companies. ProPublica. 2019. Available: https://www.propublica.org/article/we-found-over-700-doctors-who-were-paid-more-than-a-million-dollars-by-drug-and-medical-device-companies. Accessed on: 11 oct. 2024.
OZIERANSKI, Piotr et al. Exposing drug industry funding of UK patient organisations. Bmj, [S.L.], p. 1-9, 22 may 2019. http://dx.doi.org/10.1136/bmj.l1806.
PEDRIQUE, Belen et al. The drug and vaccine landscape for neglected diseases (2000-11): a systematic assessment. The Lancet Global Health, [S.L.], v. 1, n. 6, p. 371-379, dec. 2013. http://dx.doi.org/10.1016/s2214-109x(13)70078-0.
PHAM‐KANTER, Genevieve. Revisiting Financial Conflicts of Interest in FDA Advisory Committees. The Milbank Quarterly, [S.L.], v. 92, n. 3, p. 446-470, sep. 2014. http://dx.doi.org/10.1111/1468-0009.12073.
PFIZER - Financial Report (2004). New York, NY: Pfizer, 2005. 67 p. Available: https://truecostofhealthcare.org/wp-content/uploads/2015/01/Pfizer_2004.87220720.pdf. Accessed on: 11 oct. 2024.
RAJKUMAR, S. Vincent. The high cost of prescription drugs: causes and solutions. Blood Cancer Journal, [S.L.], v. 10, n. 6, p. 1, 23 jun. 2020. http://dx.doi.org/10.1038/s41408-020-0338-x.
REUTERS - News Agency. Merck Sees Slightly Higher 2007 Earnings. The New York Times. 2006. Available: https://www.nytimes.com/2006/12/07/business/07drug.html. Accessed on: 11 oct. 2024.
ROBBINS, Rebecca. How a Drug Company Made $114 Billion by Gaming the U.S. Patent System. The New York Times. 2023. Available: https://www.nytimes.com/2023/01/28/business/humira-abbvie-monopoly.html. Accessed on: 11 oct. 2024.
SISMONDO, Sergio. Ghost Management: how much of the medical literature is shaped behind the scenes by the pharmaceutical industry?. Plos Medicine, [S.L.], v. 4, n. 9, p. 286, 25 sep. 2007. http://dx.doi.org/10.1371/journal.pmed.0040286.
SISMONDO, Sergio. Pharmaceutical company funding and its consequences: a qualitative systematic review. Contemporary Clinical Trials, [S.L.], v. 29, n. 2, p. 109-113, mar. 2008. http://dx.doi.org/10.1016/j.cct.2007.08.001.
SOMO - investigates multinationals. Public health over pharmaceutical profit. 2024. Available: https://www.somo.nl/our-work/sectors/pharmaceutical-industry/. Accessed on: 11 oct. 2024.
SPIELMANS, Glen I. et al. From Evidence-based Medicine to Marketing-based Medicine: evidence from internal industry documents. Journal of Bioethical Inquiry, [S.L.], v. 7, n. 1, p. 13-29, 21 jan. 2010. http://dx.doi.org/10.1007/s11673-010-9208-8.
STACCIARINI, João Henrique Santana. The Consolidation of the Pharmaceutical Sector in the Global Economy: growth, influence, deviations, and marketing. 2023. 145 p. PhD Thesis - Geography, Universidade Federal de Goiás, Goiânia (Brazil), 2023. https://doi.org/10.5281/zenodo.10377840.
STACCIARINI, João Henrique Santana. Drug advertising in Brazil. Sociedade & Natureza, [S.L.], v. 36, n. 1, p. e72114, 4 jul. 2024c. http://dx.doi.org/10.14393/sn-v36-2024-72114x.
STACCIARINI, João Henrique Santana. O Setor Farmacêutico Global: números e dinâmicas. Caminhos de Geografia, [S.L.], v. 25, n. 101, p. 240, 3 out. 2024a. http://dx.doi.org/10.14393/rcg2510171398.
STACCIARINI, João Henrique Santana. Research and Development (R&D) in the Pharmaceutical Sector. Revista Terceiro Incluído, [S.L.], v. 14, n. 1, p. e14109, 6 ago. 2024b. http://dx.doi.org/10.5216/teri.v14i1.79594.
STATISTA. Revenue of the worldwide pharmaceutical market from 2001 to 2023. 2024. Available: https://www.statista.com/statistics/263102/pharmaceutical-market-worldwide-revenue-since-2001/. Accessed on: 11 oct. 2024.
TABATABAVAKILI, Sahar et al. Financial Conflicts of Interest in Clinical Practice Guidelines: a systematic review. Mayo Clinic Proceedings: Innovations, Quality & Outcomes, [S.L.], v. 5, n. 2, p. 466 - 475, apr. 2021. http://dx.doi.org/10.1016/j.mayocpiqo.2020.09.016.
THOMAS, Katie. Bayer and Johnson & Johnson Settle lawsuits over xarelto, a blood thinner, for $775 million. The New York Times. 2019. Available: https://www.nytimes.com/2019/03/25/health/xarelto-blood-thinner-lawsuit-settlement.html. Accessed on: 11 oct. 2024.
THOMASE, Katie; SCHMIDT, Michael S. Glaxo Agrees to Pay $3 Billion in Fraud Settlement. The New York Times. 2012. Available: https://www.nytimes.com/2012/07/03/business/glaxosmithkline-agrees-to-pay-3-billion-in-fraud-settlement.html. Accessed on: 11 oct. 2024.
TOPOL, Eric J. Failing the Public Health - Rofecoxib, Merck, and the FDA. New England Journal of Medicine, [S.L.], v. 351, n. 17, p. 1707-1709, 21 oct. 2004. http://dx.doi.org/10.1056/nejmp048286.
TORBATI, Yeganeh; O'CONNELL, Jonathan. Pharmaceutical industry likely to shatter its lobbying record as it works to shape Democrats’ spending bill. The Washington Post. Washington, D.C., U.S. nov. 2021. Available: https://www.washingtonpost.com/business/2021/11/05/pharmaceutical-industry-drug-price-lobbying/. Accessed on: 11 oct. 2024.
TROUILLER, Patrice et al. Drug development for neglected diseases: a deficient market and a public-health policy failure. The Lancet, [S.L.], v. 359, n. 9324, p. 2188-2194, jun. 2002. http://dx.doi.org/10.1016/s0140-6736(02)09096-7.
UNITED STATES. Department of Justice (U.S): Civil Division nº 12-842. Glaxosmithkline to plead guilty and pay $3 billion to resolve fraud allegations and failure to report safety data. Washington, D.C., 02 jul. 2012. Available: https://www.justice.gov/opa/pr/glaxosmithkline-plead-guilty-and-pay-3-billion-resolve-fraud-allegations-and-failure-report . Accessed on: 11 oct. 2024.
UNITED STATES. Department Of Justice (U.S): Civil Division nº 10-487. Pharmaceutical Giant AstraZeneca to Pay $520 Million for off label Drug Marketing. Washington, D.C., 27 apr. 2010. Available: https://www.justice.gov/opa/pr/pharmaceutical-giant-astrazeneca-pay-520-million-label-drug-marketing. Accessed on: 11 oct. 2024.
UNITED STATES. Department Of Justice (U.S): Civil Division nº 11-1524. U.S. pharmaceutical company Merck Sharp & Dohme to pay nearly one billion dollars over promotion of Vioxx. Washington, D.C., 22 nov. 2011. Available: https://www.justice.gov/opa/pr/us-pharmaceutical-company-merck-sharp-dohme-pay-nearly-one-billion-dollars-over-promotion. Accessed on: 11 oct. 2024.
VAN LUIJN, Johan C. F. et al. Superior efficacy of new medicines? European Journal of Clinical Pharmacology, [S.L.], v. 66, n. 5, p. 445-448, mar. 2010. http://dx.doi.org/10.1007/s00228-010-0808-3.
WAZANA, Ashley. Physicians and the Pharmaceutical Industry. Jama, [S.L.], v. 283, n. 3, p. 373, 19 jan. 2000. http://dx.doi.org/10.1001/jama.283.3.373.
WIESELER, Beate et al. New drugs: where did we go wrong and what can we do better?. Bmj, [S.L.], p. 4340, 10 jul. 2019. http://dx.doi.org/10.1136/bmj.l4340.
YEH, James S. et al. Association of Industry Payments to Physicians with the Prescribing of Brand-name Statins in Massachusetts. Jama Internal Medicine, [S.L.], v. 176, n. 6, p. 763, 1 jun. 2016. http://dx.doi.org/10.1001/jamainternmed.2016.1709.
Downloads
Publicado
Como Citar
Edição
Seção
Licença
Copyright (c) 2024 João Henrique Santana Stacciarini
Este trabalho está licenciado sob uma licença Creative Commons Attribution-ShareAlike 4.0 International License.
